AI capability is advancing fast. In some domains, it is solving problems that were out of reach just a few years ago. But ...

Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming ...

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a ...

Wondering if Repligen at around US$113 is starting to look interesting on price, or if the recent weakness is telling you to be cautious about its value? The stock closed at US$113.11, with returns of ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The popular research ...

Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) will be reporting results this Tuesday before market hours. Here’s what to expect. Repligen beat analysts’ revenue expectations last ...

Stocks, especially the once high flying technology stocks, had a lousy start to the new year. QQQ lost 9% of its value in January. We aren’t certain about the bubbly technology stocks that trade for ...

The stock price of Repligen (NASDAQ: RGEN), a U.S.-based life sciences company involved in production of materials used in the manufacture of biological drugs, has seen a 12% drop over the last twenty ...

TimesSquare Capital Management, an equity investment management company, released its “U.S. Mid Cap Growth Strategy” third-quarter investor letter. A copy of the same can be downloaded here. In the ...

Regenera Insights Inc. Annual stock financials by MarketWatch. View the latest RGEN financial statements, income statements and financial ratios.